ArticleAmerican journal of nuclear medicine and molecular imaging2015
Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma.
Article in American journal of nuclear medicine and molecular imaging, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Feasibility of [Diagnostics (Basel, Switzerland) · 2025Article
- Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma.Journal of bone oncology · 2025Review
- Imaging of Multiple Myeloma: Present and Future.Journal of clinical medicine · 2024Review
- Advanced Imaging in Multiple Myeloma: New Frontiers for MRI.Diagnostics (Basel, Switzerland) · 2022Review
- Molecular Imaging in Multiple Myeloma-Novel PET Radiotracers Improve Patient Management and Guide Therapy.Frontiers in nuclear medicine · 2022Review
- Comparison of [Diagnostics (Basel, Switzerland) · 2021Review
- Review
- Review
- Improving MR sequence of 18F-FDG PET/MR for diagnosing and staging gastric Cancer: a comparison study toCancer imaging : the official publication of the International Cancer Imaging Society · 2020Article
- Positron Emission Tomography (PET) Radiopharmaceuticals in Multiple Myeloma.Molecules (Basel, Switzerland) · 2019Review
- Imaging in myeloma with focus on advanced imaging techniques.The British journal of radiology · 2019Review
- Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI.Annals of hematology · 2019Article
- Article
- Diagnostic performance ofJapanese journal of radiology · 2018Article
- Advanced Imaging of Multiple Myeloma Bone Disease.Frontiers in endocrinology · 2018Review
- PET/MRI: Where might it replace PET/CT?Journal of magnetic resonance imaging : JMRI · 2017Review
- The Critical Role of Imaging in the Management of Multiple Myeloma.Current hematologic malignancy reports · 2017Review
- Therapy for Relapsed Multiple Myeloma: Guidelines From the Mayo Stratification for Myeloma and Risk-Adapted Therapy.Mayo Clinic proceedings · 2017Review
- Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.European journal of nuclear medicine and molecular imaging · 2017Review
- Treatment response evaluation withEuropean journal of nuclear medicine and molecular imaging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PET/MRI represents a promising hybrid imaging modality with several potential clinical applications. Although PET/MRI seems highly attractive in the diagnostic approach of multiple myeloma (MM), its role has not yet been evaluated. The aims of this prospective study are to evaluate the feasibility of (18)F-FDG PET/MRI in detection of MM lesions, and to investigate the reproducibility of bone marrow lesions detection and quantitative data of (18)F-FDG uptake between the functional (PET) component of PET/CT and PET/MRI in MM patients. The study includes 30 MM patients. All patients initially underwent (18)F-FDG PET/CT (60 min p.i.), followed by PET/MRI (120 min p.i.). PET/CT and PET/MRI data were assessed and compared based on qualitative (lesion detection) and quantitative (SUV) evaluation. The hybrid PET/MRI system provided good image quality in all cases without artefacts. PET/MRI identified 65 of the 69 lesions, which were detectable with PET/CT (94.2%). Quantitative PET evaluations showed the following mean values in MM lesions: SUVaverage=5.5 and SUVmax=7.9 for PET/CT; SUVaverage=3.9 and SUVmax=5.8 for PET/MRI. Both SUVaverage and SUVmax were significantly higher on PET/CT than on PET/MRI. Spearman correlation analysis demonstrated a strong correlation between both lesional SUVaverage (r=0.744) and lesional SUVmax (r=0.855) values derived from PET/CT and PET/MRI. Regarding detection of myeloma skeletal lesions, PET/MRI exhibited equivalent performance to PET/CT. In terms of tracer uptake quantitation, a significant correlation between the two techniques was demonstrated, despite the statistically significant differences in lesional SUVs between PET/CT and PET/MRI.
Indexed as
Identifiers
26550538PMC4620174What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.